Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

The Patient Matters in the End(point)

Date/Time

December 07, 2022

Discussion Topic

When using digital health technology (DHT) in clinical trials, we need to specify an endpoint. However, does your digital endpoint matter to the patients? Is it based in the context of their life? For regulatory purposes this seems to be an imperative. As such “black box” algorithms, despite their many benefits such as high predictive accuracy, could be a barrier to gaining a label claim.
This paper discusses the difference between a digital biomarker and a digital clinical outcomes assessment. We build on the foundations by focussing on the meaningful aspects of health and suggesting a framework for DHT development based on the DiMe Playbook. We will also go one step further in this talk than we did in the paper. Here we will and start blue sky thinking about how to combine the highly predictive algorithms underlying digital biomarkers with the patient relevant aspects of digital clinical outcomes assessments. This discussion will move us closer to  deriving patient relevant endpoints which can be enacted on an enhanced timeline.

Share This Page

Sign up to receive our monthly updates


Engage with the dime community on slack


USING A DIME RESOURCE? Share your story


Contact Us


Copyright © 2022 The Digital Medicine Society (DiMe). All Rights Reserved.